Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 34 | 2022 | 5349 | 4.580 |
Why?
|
Melanoma | 26 | 2022 | 5503 | 3.980 |
Why?
|
Nevus, Pigmented | 10 | 2022 | 219 | 3.910 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 5 | 2022 | 64 | 3.110 |
Why?
|
Dermatology | 10 | 2022 | 846 | 2.160 |
Why?
|
Melanosis | 3 | 2022 | 69 | 1.750 |
Why?
|
Basal Cell Nevus Syndrome | 2 | 2022 | 44 | 1.680 |
Why?
|
Skin | 9 | 2021 | 4319 | 0.980 |
Why?
|
Callosities | 1 | 2021 | 4 | 0.920 |
Why?
|
DNA, Neoplasm | 2 | 2020 | 1789 | 0.890 |
Why?
|
Granuloma | 2 | 2018 | 330 | 0.890 |
Why?
|
Sunburn | 2 | 2019 | 150 | 0.880 |
Why?
|
Nevus of Ota | 1 | 2021 | 4 | 0.870 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 25 | 0.870 |
Why?
|
Pigmentation Disorders | 1 | 2021 | 104 | 0.860 |
Why?
|
Granuloma, Pyogenic | 1 | 2021 | 50 | 0.860 |
Why?
|
Skin Abnormalities | 1 | 2021 | 60 | 0.850 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2020 | 14 | 0.850 |
Why?
|
Penicillamine | 1 | 2020 | 66 | 0.850 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 76 | 0.820 |
Why?
|
Carcinoma, Basal Cell | 3 | 2020 | 515 | 0.820 |
Why?
|
Nevus | 1 | 2022 | 204 | 0.800 |
Why?
|
Cumulative Trauma Disorders | 1 | 2021 | 142 | 0.800 |
Why?
|
Sentinel Lymph Node Biopsy | 5 | 2020 | 654 | 0.790 |
Why?
|
Skin Diseases | 4 | 2021 | 1079 | 0.710 |
Why?
|
Fingers | 1 | 2021 | 516 | 0.690 |
Why?
|
Aluminum Compounds | 1 | 2018 | 54 | 0.690 |
Why?
|
Dermoscopy | 1 | 2018 | 50 | 0.670 |
Why?
|
Child | 33 | 2022 | 73998 | 0.630 |
Why?
|
Hypersensitivity, Delayed | 1 | 2018 | 524 | 0.620 |
Why?
|
Cleft Lip | 1 | 2021 | 412 | 0.620 |
Why?
|
Urticaria | 1 | 2018 | 157 | 0.610 |
Why?
|
Cleft Palate | 1 | 2021 | 495 | 0.610 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 590 | 0.580 |
Why?
|
Sweat Gland Diseases | 1 | 2015 | 11 | 0.580 |
Why?
|
Drug Eruptions | 3 | 2014 | 304 | 0.580 |
Why?
|
Eccrine Glands | 1 | 2015 | 50 | 0.550 |
Why?
|
Chlorides | 1 | 2018 | 714 | 0.540 |
Why?
|
Urinary Bladder | 5 | 2008 | 1127 | 0.520 |
Why?
|
Abnormalities, Multiple | 1 | 2021 | 1375 | 0.510 |
Why?
|
Leg Injuries | 1 | 2015 | 184 | 0.480 |
Why?
|
Hamartoma | 1 | 2015 | 233 | 0.480 |
Why?
|
Telemedicine | 4 | 2022 | 2552 | 0.480 |
Why?
|
Biopsy | 7 | 2021 | 6786 | 0.470 |
Why?
|
Language | 1 | 2021 | 1211 | 0.470 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 865 | 0.460 |
Why?
|
Giant Cells | 1 | 2013 | 183 | 0.460 |
Why?
|
Clobetasol | 2 | 2014 | 32 | 0.440 |
Why?
|
Anti-Inflammatory Agents | 2 | 2012 | 1808 | 0.420 |
Why?
|
Cyclin D1 | 1 | 2013 | 490 | 0.410 |
Why?
|
Pyoderma Gangrenosum | 1 | 2010 | 75 | 0.380 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 569 | 0.370 |
Why?
|
Hair Diseases | 1 | 2009 | 76 | 0.370 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 274 | 0.360 |
Why?
|
Ultraviolet Rays | 1 | 2014 | 1071 | 0.350 |
Why?
|
Humans | 67 | 2022 | 709431 | 0.350 |
Why?
|
Pathology, Clinical | 1 | 2012 | 362 | 0.350 |
Why?
|
Exocytosis | 3 | 2008 | 367 | 0.330 |
Why?
|
Adolescent | 19 | 2021 | 85327 | 0.310 |
Why?
|
Eczema | 2 | 2018 | 205 | 0.300 |
Why?
|
Child, Preschool | 14 | 2021 | 41195 | 0.290 |
Why?
|
Vaccination | 1 | 2018 | 2847 | 0.290 |
Why?
|
Diagnosis, Differential | 5 | 2021 | 13362 | 0.260 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1850 | 0.230 |
Why?
|
Dermatitis, Atopic | 2 | 2019 | 619 | 0.220 |
Why?
|
Trientine | 1 | 2020 | 12 | 0.220 |
Why?
|
Pamphlets | 1 | 2020 | 74 | 0.210 |
Why?
|
Infant | 10 | 2022 | 34274 | 0.210 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2021 | 133 | 0.200 |
Why?
|
Melanins | 1 | 2022 | 290 | 0.200 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4425 | 0.200 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 4500 | 0.190 |
Why?
|
Glucocorticoids | 2 | 2021 | 2109 | 0.190 |
Why?
|
Aminoquinolines | 1 | 2020 | 109 | 0.190 |
Why?
|
Genomics | 2 | 2022 | 5250 | 0.190 |
Why?
|
Lip | 1 | 2021 | 182 | 0.190 |
Why?
|
Retrospective Studies | 13 | 2022 | 71151 | 0.190 |
Why?
|
Young Adult | 9 | 2021 | 56163 | 0.180 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4020 | 0.170 |
Why?
|
Female | 28 | 2022 | 377269 | 0.170 |
Why?
|
Communication Barriers | 1 | 2021 | 365 | 0.170 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2008 | 182 | 0.170 |
Why?
|
Patch Tests | 1 | 2018 | 57 | 0.170 |
Why?
|
Ambulatory Care Facilities | 2 | 2021 | 879 | 0.170 |
Why?
|
Histamine Antagonists | 1 | 2018 | 101 | 0.160 |
Why?
|
Sunlight | 1 | 2019 | 333 | 0.160 |
Why?
|
Remote Consultation | 1 | 2020 | 251 | 0.160 |
Why?
|
Urination | 1 | 2008 | 190 | 0.160 |
Why?
|
rab GTP-Binding Proteins | 1 | 2008 | 242 | 0.160 |
Why?
|
Male | 24 | 2022 | 351848 | 0.160 |
Why?
|
Comparative Genomic Hybridization | 1 | 2018 | 514 | 0.150 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2019 | 5125 | 0.150 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6123 | 0.150 |
Why?
|
Antibodies, Monoclonal | 2 | 2012 | 9857 | 0.140 |
Why?
|
Acneiform Eruptions | 1 | 2014 | 5 | 0.140 |
Why?
|
Dermatitis, Phototoxic | 1 | 2014 | 16 | 0.140 |
Why?
|
Health Services Accessibility | 3 | 2022 | 4996 | 0.140 |
Why?
|
Parents | 2 | 2019 | 3174 | 0.140 |
Why?
|
Neurons, Afferent | 1 | 2007 | 520 | 0.140 |
Why?
|
Mohs Surgery | 1 | 2017 | 182 | 0.140 |
Why?
|
Fluorouracil | 1 | 2020 | 1641 | 0.130 |
Why?
|
Immunohistochemistry | 4 | 2017 | 11904 | 0.130 |
Why?
|
Antifungal Agents | 2 | 2019 | 714 | 0.130 |
Why?
|
Receptors, Purinergic P2 | 1 | 2005 | 159 | 0.130 |
Why?
|
Hyperalgesia | 1 | 2008 | 499 | 0.130 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1684 | 0.130 |
Why?
|
Photography | 1 | 2017 | 535 | 0.120 |
Why?
|
Interferons | 1 | 2017 | 680 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2014 | 1936 | 0.120 |
Why?
|
Physostigmine | 1 | 2002 | 58 | 0.120 |
Why?
|
Urothelium | 1 | 2005 | 290 | 0.120 |
Why?
|
Estrous Cycle | 1 | 2002 | 65 | 0.120 |
Why?
|
Adult | 11 | 2022 | 212298 | 0.120 |
Why?
|
Pemphigoid, Bullous | 1 | 2014 | 104 | 0.120 |
Why?
|
Administration, Topical | 2 | 2014 | 705 | 0.120 |
Why?
|
Leg | 1 | 2018 | 1161 | 0.110 |
Why?
|
Laminin | 1 | 2014 | 425 | 0.110 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2013 | 216 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2018 | 933 | 0.110 |
Why?
|
Lower Extremity | 2 | 2017 | 1038 | 0.110 |
Why?
|
Documentation | 1 | 2018 | 854 | 0.110 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 349 | 0.110 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2669 | 0.110 |
Why?
|
Prognosis | 3 | 2019 | 29148 | 0.110 |
Why?
|
Cholinesterase Inhibitors | 1 | 2002 | 237 | 0.100 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3740 | 0.100 |
Why?
|
Caregivers | 1 | 2022 | 1894 | 0.100 |
Why?
|
Alopecia | 2 | 2018 | 352 | 0.100 |
Why?
|
Rheumatoid Nodule | 1 | 2010 | 18 | 0.100 |
Why?
|
Necrobiosis Lipoidica | 1 | 2010 | 11 | 0.100 |
Why?
|
Xanthomatosis | 1 | 2010 | 35 | 0.100 |
Why?
|
Measles | 1 | 2012 | 173 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3535 | 0.100 |
Why?
|
Pituitary-Adrenal System | 1 | 2002 | 505 | 0.100 |
Why?
|
Mutation | 1 | 2014 | 29242 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2785 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2012 | 624 | 0.090 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1010 | 0.090 |
Why?
|
Curriculum | 1 | 2022 | 3312 | 0.090 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 666 | 0.090 |
Why?
|
Reference Standards | 1 | 2012 | 890 | 0.090 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 1753 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20307 | 0.090 |
Why?
|
Survivors | 1 | 2019 | 2141 | 0.090 |
Why?
|
Lichen Planus | 1 | 2009 | 53 | 0.090 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2002 | 656 | 0.090 |
Why?
|
Patient Compliance | 1 | 2019 | 2765 | 0.090 |
Why?
|
Age Factors | 4 | 2020 | 18954 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2013 | 12446 | 0.090 |
Why?
|
Cell Membrane | 2 | 2007 | 3924 | 0.090 |
Why?
|
Patient Care Team | 2 | 2019 | 2596 | 0.090 |
Why?
|
Sjogren's Syndrome | 1 | 2010 | 233 | 0.090 |
Why?
|
Referral and Consultation | 3 | 2021 | 3448 | 0.090 |
Why?
|
Dermatitis | 1 | 2010 | 191 | 0.090 |
Why?
|
Adenosine Triphosphate | 1 | 2005 | 2216 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 8864 | 0.080 |
Why?
|
Interleukins | 1 | 2012 | 807 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1891 | 0.080 |
Why?
|
Paraproteinemias | 1 | 2010 | 242 | 0.080 |
Why?
|
Postoperative Complications | 1 | 2010 | 15035 | 0.080 |
Why?
|
Eosinophils | 1 | 2012 | 927 | 0.080 |
Why?
|
Health Behavior | 1 | 2019 | 2590 | 0.080 |
Why?
|
Biological Specimen Banks | 1 | 2012 | 620 | 0.080 |
Why?
|
Massachusetts | 1 | 2020 | 8754 | 0.080 |
Why?
|
Lipomatosis | 1 | 2007 | 111 | 0.080 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1087 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8941 | 0.080 |
Why?
|
Hair | 1 | 2009 | 467 | 0.070 |
Why?
|
Appointments and Schedules | 2 | 2020 | 427 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1406 | 0.070 |
Why?
|
Intestine, Small | 1 | 2012 | 1235 | 0.070 |
Why?
|
Survival Rate | 2 | 2018 | 13363 | 0.070 |
Why?
|
Autoantibodies | 1 | 2014 | 1982 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4325 | 0.070 |
Why?
|
Genetic Testing | 1 | 2018 | 3299 | 0.070 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4228 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2017 | 11244 | 0.070 |
Why?
|
Diagnostic Errors | 1 | 2012 | 1261 | 0.070 |
Why?
|
Cohort Studies | 3 | 2018 | 39650 | 0.070 |
Why?
|
Sarcoidosis | 1 | 2010 | 516 | 0.070 |
Why?
|
Incidence | 2 | 2020 | 20587 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2014 | 1569 | 0.060 |
Why?
|
Bone Marrow Transplantation | 1 | 2012 | 2789 | 0.060 |
Why?
|
Immunotherapy | 1 | 2019 | 4114 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3946 | 0.060 |
Why?
|
Methotrexate | 1 | 2010 | 1710 | 0.060 |
Why?
|
Risk Factors | 7 | 2020 | 70264 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2019 | 10858 | 0.060 |
Why?
|
Staphylococcus aureus | 1 | 2010 | 1393 | 0.060 |
Why?
|
Hypertrichosis | 1 | 2021 | 31 | 0.060 |
Why?
|
Skin Care | 1 | 2021 | 53 | 0.060 |
Why?
|
Hair Removal | 1 | 2021 | 36 | 0.050 |
Why?
|
Neurocutaneous Syndromes | 1 | 2021 | 40 | 0.050 |
Why?
|
Cross-Sectional Studies | 5 | 2021 | 22944 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39394 | 0.050 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13763 | 0.050 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 2807 | 0.050 |
Why?
|
Electronics | 1 | 2021 | 295 | 0.050 |
Why?
|
Antirheumatic Agents | 1 | 2010 | 1356 | 0.050 |
Why?
|
Rabbits | 2 | 2007 | 5242 | 0.050 |
Why?
|
Stem Cells | 1 | 2012 | 3600 | 0.040 |
Why?
|
Pruritus | 1 | 2021 | 339 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1900 | 0.040 |
Why?
|
Cytoplasmic Vesicles | 1 | 2008 | 79 | 0.040 |
Why?
|
Emollients | 1 | 2018 | 32 | 0.040 |
Why?
|
Cystitis | 1 | 2008 | 87 | 0.040 |
Why?
|
Reflex, Abnormal | 1 | 2008 | 85 | 0.040 |
Why?
|
Baths | 1 | 2018 | 52 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 34096 | 0.040 |
Why?
|
Primary Health Care | 3 | 2020 | 4483 | 0.040 |
Why?
|
Nail Diseases | 1 | 2018 | 55 | 0.040 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2010 | 2085 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2022 | 2190 | 0.040 |
Why?
|
Risk Assessment | 2 | 2017 | 23519 | 0.040 |
Why?
|
Vitiligo | 1 | 2018 | 93 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5227 | 0.040 |
Why?
|
Cell Shape | 1 | 2008 | 378 | 0.040 |
Why?
|
Middle Aged | 6 | 2018 | 215428 | 0.040 |
Why?
|
Quality of Life | 1 | 2018 | 11553 | 0.040 |
Why?
|
Iatrogenic Disease | 1 | 2020 | 520 | 0.040 |
Why?
|
Transforming Growth Factor alpha | 1 | 2007 | 139 | 0.040 |
Why?
|
Crohn Disease | 1 | 2010 | 2277 | 0.040 |
Why?
|
Cycloheximide | 1 | 2007 | 364 | 0.040 |
Why?
|
Early Detection of Cancer | 2 | 2021 | 2842 | 0.040 |
Why?
|
Neutrophils | 1 | 2010 | 3865 | 0.040 |
Why?
|
Phenotype | 1 | 2014 | 16295 | 0.040 |
Why?
|
Nurse Practitioners | 1 | 2019 | 274 | 0.040 |
Why?
|
Mutant Proteins | 1 | 2008 | 512 | 0.040 |
Why?
|
Capital Financing | 1 | 2016 | 56 | 0.040 |
Why?
|
Electric Capacitance | 1 | 2005 | 11 | 0.040 |
Why?
|
Receptors, Purinergic P2X3 | 1 | 2005 | 9 | 0.040 |
Why?
|
Purinergic P2 Receptor Agonists | 1 | 2005 | 13 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8733 | 0.040 |
Why?
|
Receptors, Purinergic P2X2 | 1 | 2005 | 14 | 0.040 |
Why?
|
Receptor, erbB-2 | 2 | 2014 | 2285 | 0.040 |
Why?
|
Waiting Lists | 1 | 2020 | 707 | 0.040 |
Why?
|
Disease Management | 2 | 2018 | 2539 | 0.040 |
Why?
|
Pyridoxal Phosphate | 1 | 2005 | 127 | 0.040 |
Why?
|
Mice, Knockout | 3 | 2012 | 15286 | 0.040 |
Why?
|
Office Visits | 1 | 2020 | 631 | 0.040 |
Why?
|
Benzoyl Peroxide | 1 | 2014 | 11 | 0.040 |
Why?
|
Brain | 1 | 2022 | 24936 | 0.040 |
Why?
|
Physical Examination | 1 | 2021 | 1249 | 0.040 |
Why?
|
Transduction, Genetic | 1 | 2008 | 976 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2019 | 61963 | 0.030 |
Why?
|
Clindamycin | 1 | 2014 | 140 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 672 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1323 | 0.030 |
Why?
|
Minocycline | 1 | 2014 | 157 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 19470 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2007 | 724 | 0.030 |
Why?
|
Mice | 5 | 2022 | 80950 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2007 | 8581 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2014 | 58752 | 0.030 |
Why?
|
Needs Assessment | 1 | 2019 | 1148 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2007 | 679 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2008 | 692 | 0.030 |
Why?
|
Sensory Receptor Cells | 1 | 2007 | 447 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 527 | 0.030 |
Why?
|
Arginine Vasopressin | 1 | 2002 | 134 | 0.030 |
Why?
|
Time Factors | 2 | 2018 | 41295 | 0.030 |
Why?
|
Apyrase | 1 | 2005 | 386 | 0.030 |
Why?
|
Sampling Studies | 1 | 2014 | 648 | 0.030 |
Why?
|
Tyrosine | 1 | 2007 | 1486 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 319 | 0.030 |
Why?
|
United States | 4 | 2021 | 67177 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 5231 | 0.030 |
Why?
|
Epithelium | 1 | 2007 | 1740 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2022 | 2463 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2012 | 23044 | 0.030 |
Why?
|
Corticosterone | 1 | 2002 | 317 | 0.030 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 687 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2013 | 324 | 0.030 |
Why?
|
Radiotherapy | 1 | 2019 | 1627 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2014 | 353 | 0.030 |
Why?
|
Mycoses | 1 | 2014 | 369 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1331 | 0.030 |
Why?
|
Interleukin-23 | 1 | 2012 | 183 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 2013 | 997 | 0.030 |
Why?
|
Receptors, Interleukin | 1 | 2012 | 250 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1436 | 0.030 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2013 | 261 | 0.030 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2002 | 629 | 0.030 |
Why?
|
Endocytosis | 1 | 2005 | 1020 | 0.030 |
Why?
|
Wound Healing | 1 | 2021 | 2792 | 0.020 |
Why?
|
Animals | 6 | 2022 | 170647 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2002 | 493 | 0.020 |
Why?
|
Psoriasis | 1 | 2018 | 983 | 0.020 |
Why?
|
Melanocytes | 1 | 2013 | 532 | 0.020 |
Why?
|
Pyridones | 1 | 2014 | 664 | 0.020 |
Why?
|
Autoantigens | 1 | 2014 | 918 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2014 | 881 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 1758 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4696 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2349 | 0.020 |
Why?
|
Signal Transduction | 3 | 2007 | 23985 | 0.020 |
Why?
|
Drug Combinations | 1 | 2014 | 1916 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1150 | 0.020 |
Why?
|
Glycoproteins | 1 | 2007 | 2315 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1089 | 0.020 |
Why?
|
Rats | 2 | 2007 | 25068 | 0.020 |
Why?
|
Pain Measurement | 1 | 2008 | 3518 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17347 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 19798 | 0.020 |
Why?
|
Aged | 3 | 2018 | 162592 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1279 | 0.020 |
Why?
|
Health Care Reform | 1 | 2016 | 1255 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 2014 | 1148 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 2927 | 0.020 |
Why?
|
Phosphorylation | 1 | 2007 | 8737 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2007 | 3688 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5233 | 0.020 |
Why?
|
Health Personnel | 1 | 2016 | 2982 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2012 | 6768 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3712 | 0.010 |
Why?
|
Pediatrics | 1 | 2018 | 3556 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 3025 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 5808 | 0.010 |
Why?
|
Physicians | 1 | 2019 | 4277 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2021 | 24403 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 2891 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 6185 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9409 | 0.010 |
Why?
|
Neoplasms | 1 | 2010 | 20421 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 6922 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 21874 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10621 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 16161 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2016 | 4747 | 0.010 |
Why?
|
Sex Factors | 1 | 2002 | 10744 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13298 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 10133 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 17087 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18384 | 0.010 |
Why?
|
HIV Infections | 1 | 2007 | 15439 | 0.000 |
Why?
|